Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

BACKGROUND: Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Riepl, Ester, Pfeuffer, Steffen, Ruck, Tobias, Lohmann, Hubertus, Wiendl, Heinz, Meuth, Sven G., Johnen, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775967/
https://www.ncbi.nlm.nih.gov/pubmed/29387035
http://dx.doi.org/10.3389/fneur.2017.00730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775967/
https://www.ncbi.nlm.nih.gov/pubmed/29387035
http://dx.doi.org/10.3389/fneur.2017.00730

Ejemplares similares